Artificial Cell Technologies, Inc. (ACT) is a development-stage biotechnology company developing unique synthetic vaccines utilizing a proprietary and patent-protected technology platform of ultra-thin multilayer polypeptide nanofilms. The companyâs headquarters and laboratory facilities are located in New Haven, CT.
ACT engineers and produces multilayer nanofilm-based vaccines using a method known as electrostatic layer-by-layer self-assembly. Polypeptides with alternating opposite net electrical charge are assembled one layer at a time and adhere to the surface by electrostatic attraction. Key immunogenic epitopes from pathogenic organisms are incorporated into the nanofilm structure or on its surface during assembly. We call the resulting synthetic antigen carriers âArtificial Virusesâ.
ACTâs technology represents an entirely new approach to vaccines that is uniquely capable of more fully mimicking the immunogenic properties of a pathogenic organism and at the same time influencing the molecular and biological pathways of immune response. â¨â¨
Advantages of ACTâs vaccine technology include:
Increases the immunogenicity of weakly or non-immunogenic antigens without the use of adjuvants
Reduces antigen dose required for immunization dramatically reducing cost of materials
Rapid synthetic manufacture with no egg or cell culture required, greatly reducing the chance of contamination and allowing a much faster time to market
Flexible design and production platform readily allows for multivalent or combination vaccines
Constructs are shelf stable at room temperature with a long shelf life; no cold chain storage required
ACT's lead product candidates are vaccines for Respiratory Syncytial Virus (RSV) and malaria. Our development programs in both RSV and malaria include collaborations with top academic as well as government partners.
ACT is now preparing its first IND filing to begin human clinical trials of an RSV vaccine candidate which utilizes ACT's proprietary ultra-thin multilayer polypepti